United Therapeutics (UTHR) Change in Receivables (2009 - 2026)

United Therapeutics has reported Change in Receivables for 18 years, with the latest figure at -$38.2 million in Q1 2026.

• Quarterly Change in Receivables fell 189.46% year-over-year to -$38.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.0 million (down 167.57% YoY) and the FY2025 annual result came in at $70.9 million, up 17625.0% from the prior year.
• Change in Receivables slipped to -$38.2 million in Q1 2026 per UTHR's latest filing, from $52.5 million in the prior quarter.
• Over five years, Change in Receivables peaked at $138.1 million in Q2 2023 and troughed at -$85.9 million in Q1 2023.
• A 5-year average of $6.7 million and a median of $2.8 million in 2022 frame the typical range for Change in Receivables.
• The sharpest annual moves came in 2023 and 2024: Change in Receivables soared 4832.14% in 2023, then tumbled 407.88% in 2024.
• Over 5 years, Change in Receivables stood at -$11.3 million in 2022, then jumped by 279.65% to $20.3 million in 2023, then sank by 407.88% to -$62.5 million in 2024, then soared by 184.0% to $52.5 million in 2025, then sank by 172.76% to -$38.2 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered -$38.2 million, $52.5 million, and -$81.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.